Actively Recruiting
Study of Personalized Tumor Neoantigen mRNA Therapy Combined With PD-1 and Anti-VEGFR Antibodies Plus TACE for Advanced Hepatocellular Carcinoma in Adults
Led by Zhejiang University · Updated on 2025-05-29
30
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and feasibility of a personalized tumor neoantigen mRNA therapy called iNeo-Vac-R01 in combination with PD-1 monoclonal antibody, anti-VEGFR monoclonal antibody, and transarterial chemoembolization TACE for patients with advanced hepatocellular carcinoma HCC. This clinical trial is designed for adults aged 18 to 75 years with unresectable or metastatic HCC, aiming to study new treatment options in advanced liver cancer. Participants will first undergo pathological diagnosis and screening, which includes starting TACE treatment up to four times with at least four weeks between procedures. Following this, patients receive intravenous infusions of sintilimab 200 mg combined with bevacizumab 15 mgkg every three weeks until intolerance or tumor progression occurs. Around week 7, if no disease progression is detected, patients will also receive personalized mRNA injections every three weeks along with continued infusions of sintilimab and bevacizumab. During the study, participants will be monitored for adverse events during dosing and follow-up periods, with safety evaluations conducted up to 21 days after the last dose. Researchers will assess objective response rate, disease control rate, conversion rate, progression-free survival, and overall survival for up to two to three years. Patients will undergo regular assessments including imaging to evaluate tumor response and will be followed for long-term outcomes and safety through the study period ending in 2028.
CONDITIONS
Brief Title
Personalized Tumor Neoantigen mRNA Therapy for Advanced Hepatocellular Carcinoma
Research Team
T
Tingbo Liang
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here